NR
NRC.F Neuronetics Inc
- Market cap
- EUR 97.2M
- P/E
- -
- P/B
- 6.84x
- ROE
- -113.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is NRC.F undervalued?
Graham numberThe Graham number of Neuronetics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Neuronetics Inc fundamental analysis
No fundamental analysis for Neuronetics Inc yet.
Neuronetics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Neuronetics Inc
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to …
Full company profileNeuronetics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Neuronetics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 34.2M | 40.4M | 52.8M | 62.7M | 49.2M | 55.3M | 65.2M | 71.3M | 74.9M | 149M | 157M |
| Gross Profit | 27.6M | 30.8M | 40.3M | 47.3M | 37.7M | 43.7M | 49.7M | 51.7M | 54.2M | 72.3M | 79.0M |
| Operating Income | -9.34M | -13.6M | -19.8M | -26.9M | -22.3M | -27.6M | -35.1M | -30.6M | -34.6M | -31.4M | -13.3M |
| EBITDA | - | -12.7M | -19.5M | -24.3M | -25.9M | -29.4M | -31.3M | -23.4M | -35.2M | -28.1M | -10.3M |
| Net Income | -11.2M | -16.1M | -24.1M | -29.0M | -27.5M | -31.2M | -37.2M | -30.2M | -43.7M | -39.0M | -21.2M |
| EPS | - | -0.96 | -1.36 | -1.56 | -1.44 | -1.18 | -1.36 | -1.04 | -0.78 | -0.57 | -0.27 |
| Balance Sheet | |||||||||||
| Total Assets | 24.8M | 38.9M | 117M | 100M | 78.7M | 141M | 117M | 116M | 141M | 142M | 132M |
| Total Liabilities | 202M | 232M | 46.0M | 52.3M | 53.2M | 56.0M | 59.8M | 81.6M | 109M | 115M | 110M |
| Shareholders' Equity | -177M | -193M | 71.0M | 47.9M | 25.5M | 85.2M | 57.1M | 34.2M | 27.7M | 22.4M | 18.7M |
| Cash & Short-term Investments | 17.0M | 29.1M | 105M | 75.7M | 49.0M | 94.1M | 70.3M | 59.7M | 18.5M | 28.1M | 22.1M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -8.54M | -11.1M | -20.6M | -30.5M | -28.4M | -28.0M | -30.7M | -32.0M | -31.0M | -20.4M | -12.3M |
| Capital Expenditure | 324K | 594K | 1.01M | 813K | 730K | 2.35M | 3.27M | 2.37M | 1.47M | 801K | 1.45M |
| Free Cash Flow | - | -11.7M | -21.6M | -31.3M | -29.1M | -30.3M | -34.0M | -34.4M | -32.5M | -21.2M | -13.7M |
| Ratios | |||||||||||
| ROE | - | - | -33.9% | -60.7% | -107.7% | -36.6% | -65.1% | -88.3% | -157.8% | -174.3% | -113.5% |
| ROA | -45.3% | -41.2% | -20.6% | -29.0% | -34.9% | -22.1% | -31.8% | -26.1% | -31.0% | -27.6% | -16.1% |
| Net Profit Margin | -32.8% | -39.7% | -45.7% | -46.4% | -55.7% | -56.4% | -57.0% | -42.3% | -58.4% | -26.1% | -13.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Neuronetics Inc dividends
Neuronetics Inc has not paid dividends in the last 9 fiscal years.
Who owns Neuronetics Inc
- Insiders 25.96%
- Institutions 42.17%
- Public & others 31.87%
- Shares outstanding 77.7M
- Free float 38.7M
Neuronetics Inc company profile
- Company name
- Neuronetics Inc
- Ticker
- NRC.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 658
- Fiscal year end
- December
- Address
- 3222 Phoenixville Pike, Malvern, PA, United States, 19355
- Phone
- 877 600 7555
- Website
- neurostar.com/neuronetics
About Neuronetics Inc
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. has a strategic collaboration with ANT Neuro to expand the capabilities of the NeuroStar advanced therapy system with advanced image-guided navigation technology. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Neuronetics Inc management
4- Mr. Daniel L. ReuversCEO, President & Director · born 1963
- Mr. Nir Naor C.F.A., CPA, L.L.M., M.B.A.Executive VP, CFO, Corporate Secretary, Principal Financial and Accounting Officer & Treasurer · born 1975
- Mr. Robert GreeneSenior Vice President of Sales
- Mr. Cory S. AndersonExecutive Vice President & General Manager of Greenbrook · born 1977